{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:47:44Z","timestamp":1792651664022,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["754364"],"award-info":[{"award-number":["754364"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.nano.2020.102178","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T03:43:08Z","timestamp":1583725388000},"page":"102178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice"],"prefix":"10.1016","volume":"26","author":[{"given":"Niusha","family":"Nikravesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Borchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Philipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Fl\u00fchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9\u201010","key":"10.1016\/j.nano.2020.102178_bb0005","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/smll.201202111","article-title":"Chemical design of biocompatible iron oxide nanoparticles for medical applications","volume":"9","author":"Ling","year":"2013","journal-title":"Small"},{"key":"10.1016\/j.nano.2020.102178_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.matchemphys.2015.04.022","article-title":"The effects of synthesis method on the physical and chemical properties of dextran coated iron oxide nanoparticles","volume":"160","author":"Hauser","year":"2015","journal-title":"Mater. Chem. Phys."},{"key":"10.1016\/j.nano.2020.102178_bb0015","first-page":"1005","article-title":"Nanotherapeutics in the EU: an overview on current state and future directions","volume":"9","author":"Hafner","year":"2014","journal-title":"Int. J. Nanomedicine"},{"issue":"6","key":"10.1016\/j.nano.2020.102178_bb0020","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/anie.200906684","article-title":"Nanoparticles in biological systems","volume":"50","author":"Stark","year":"2011","journal-title":"Angew. Chemie Int. Ed."},{"issue":"5","key":"10.1016\/j.nano.2020.102178_bb0025","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/anie.200802585","article-title":"Nanomedicine\u2014challenge and perspectives","volume":"48","author":"Riehemann","year":"2009","journal-title":"Angew. Chemie Int. Ed."},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02707191","article-title":"Colloid chemical approach to nanotechnology","volume":"18","author":"Fendler","year":"2001","journal-title":"Korean J. Chem. Eng."},{"key":"10.1016\/j.nano.2020.102178_bb0035","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.2147\/IJN.S46900","article-title":"Nanopharmaceuticals (part 1): products on the market","volume":"9","author":"Weissig","year":"2014","journal-title":"Int. J. Nanomedicine"},{"issue":"6","key":"10.1016\/j.nano.2020.102178_bb0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5581\/1516-8484.20110123","article-title":"Intravenous iron therapy: how far have we come?","volume":"33","author":"Can\u00e7ado","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"10.1016\/j.nano.2020.102178_bb0045","doi-asserted-by":"crossref","unstructured":"S. M\u00fchlebach and B. Fl\u00fchmann, \u201cIron carbohydrate complexes: characteristics and regulatory challenges,\u201d in Non-Biological Complex Drugs, Springer, 2015, pp. 149\u2013170.","DOI":"10.1007\/978-3-319-16241-6_5"},{"key":"10.1016\/j.nano.2020.102178_bb0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.biomaterials.2016.11.025","article-title":"Iron nanomedicines induce Toll-like receptor activation, cytokine production and complement activation","volume":"119","author":"Verhoef","year":"2017","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0055","first-page":"13","article-title":"Safety and efficacy of intravenous administration of iron preparations","volume":"74","author":"Grzywacz","year":"2017","journal-title":"Acta Pol. Pharm."},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0060","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ajh.20056","article-title":"Parenteral iron therapy options","volume":"76","author":"Silverstein","year":"2004","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.nano.2020.102178_bb0065","doi-asserted-by":"crossref","unstructured":"J. R. Connor, X. Zhang, A. M. Nixon, B. Webb, and J. R. Perno, \u201cComparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations,\u201d PLoS One, vol. 10, no. 5, p. e0125272, 2015.","DOI":"10.1371\/journal.pone.0125272"},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0070","first-page":"66","article-title":"Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model","volume":"11","author":"Eduardo Toblli","year":"2012","journal-title":"Inflamm. Allergy-Drug Targets (Formerly Curr. Drug Targets-Inflammation Allergy)"},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics3010012","article-title":"The pharmacokinetics and pharmacodynamics of iron preparations","volume":"3","author":"Geisser","year":"2011","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.nano.2020.102178_bb0080","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.nano.2013.12.011","article-title":"A nano-disperse ferritin-core mimetic that efficiently corrects anemia without luminal iron redox activity","volume":"10","author":"Powell","year":"2014","journal-title":"Nanomedicine Nanotechnology, Biol. Med."},{"issue":"6","key":"10.1016\/j.nano.2020.102178_bb0085","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bjhh.2015.08.012","article-title":"Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia","volume":"37","author":"Friedrisch","year":"2015","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"10.1016\/j.nano.2020.102178_bb0090","unstructured":"H. Saito, \u201cMetabolism of iron stores,\u201d Nagoya J. Med. Sci., vol. 76, no. 3\u20134, p. 235, 2014."},{"key":"10.1016\/j.nano.2020.102178_bb0095","doi-asserted-by":"crossref","unstructured":"D. Sun et al., \u201cComparative evaluation of US brand and generic intravenous sodium ferric gluconate complex in sucrose injection: physicochemical characterization,\u201d Nanomaterials, vol. 8, no. 1, p. 25, 2018.","DOI":"10.3390\/nano8010025"},{"key":"10.1016\/j.nano.2020.102178_bb0100","doi-asserted-by":"crossref","unstructured":"M. Koralewski, M. Pochylski, and J. Gierszewski, \u201cMagnetic properties of ferritin and akaganeite nanoparticles in aqueous suspension,\u201d J. Nanoparticle Res., vol. 15, no. 9, p. 1902, 2013.","DOI":"10.1007\/s11051-013-1902-0"},{"issue":"10","key":"10.1016\/j.nano.2020.102178_bb0105","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1007\/s00604-017-2388-8","article-title":"The fate of iron nanoparticles used for treatment of iron deficiency in blood using mass-spectrometry based strategies","volume":"184","author":"Garc\u00eda-Fern\u00e1ndez","year":"2017","journal-title":"Microchim. Acta"},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0110","first-page":"338","article-title":"Clinical use of intravenous iron: administration, efficacy, and safety","volume":"2010","author":"Auerbach","year":"2010","journal-title":"ASH Educ. Progr. B."},{"issue":"4","key":"10.1016\/j.nano.2020.102178_bb0115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10534-015-9845-9","article-title":"Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose","volume":"28","author":"Neiser","year":"2015","journal-title":"Biometals"},{"issue":"1\u20132","key":"10.1016\/j.nano.2020.102178_bb0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2016.03.029","article-title":"Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy","volume":"505","author":"Wu","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.nano.2020.102178_bb0125","doi-asserted-by":"crossref","unstructured":"V. Ayala, A. P. Herrera, M. Latorre-Esteves, M. Torres-Lugo, and C. Rinaldi, \u201cEffect of surface charge on the colloidal stability and in vitro uptake of carboxymethyl dextran-coated iron oxide nanoparticles,\u201d J. Nanoparticle Res., vol. 15, no. 8, p. 1874, 2013.","DOI":"10.1007\/s11051-013-1874-0"},{"issue":"suppl 2","key":"10.1016\/j.nano.2020.102178_bb0130","first-page":"S93","article-title":"Structure, chemistry, and pharmacokinetics of intravenous iron agents","volume":"15","author":"Danielson","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.nano.2020.102178_bb0135","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jinorgbio.2004.06.010","article-title":"Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations","volume":"98","author":"Kudasheva","year":"2004","journal-title":"J. Inorg. Biochem."},{"issue":"3","key":"10.1016\/j.nano.2020.102178_bb0140","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/ndt\/gfg579","article-title":"Labile iron in parenteral iron formulations: a quantitative and comparative study","volume":"19","author":"Van Wyck","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"issue":"SUPPL. 2","key":"10.1016\/j.nano.2020.102178_bb0145","first-page":"107","article-title":"Labile iron: manifestations and clinical implications","volume":"15","author":"Van Wyck","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.nano.2020.102178_bb0150","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10534-016-9923-7","article-title":"Ferrous iron content of intravenous iron formulations","volume":"29","author":"Gupta","year":"2016","journal-title":"Biometals"},{"key":"10.1016\/j.nano.2020.102178_bb0155","doi-asserted-by":"crossref","unstructured":"F. Funk, P. Ryle, C. Canclini, S. Neiser, and P. Geisser, \u201cThe new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose,\u201d Arzneimittel-Forschung\/Drug Res., vol. 60, no. 6, p. 345, 2010.","DOI":"10.1055\/s-0031-1296299"},{"issue":"2","key":"10.1016\/j.nano.2020.102178_bb0160","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.yrtph.2012.08.009","article-title":"Nanoparticle iron medicinal products \u2014 requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies","volume":"64","author":"Borchard","year":"2012","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.nano.2020.102178_bb0165","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijpharm.2014.01.008","article-title":"Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: Iron sucrose","volume":"464","author":"Shah","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.nano.2020.102178_bb0170","unstructured":"\u201cGuideline for elemental impurities Q3D.\u201d [Online]. Available: https:\/\/www.ich.org\/products\/guidelines\/quality\/article\/quality-guidelines.html."},{"key":"10.1016\/j.nano.2020.102178_bb0175","series-title":"Iron preparations and methods of makeng and administering the same","author":"John","year":"1979"},{"key":"10.1016\/j.nano.2020.102178_bb0180","doi-asserted-by":"crossref","unstructured":"J. T. Mahajan Purbita Chakraborty, \u201cEffect of variation of process parameters on stability of colloidal metal-complexes,\u201d Der Pharma Chem., vol. 9, no. 9, pp. 19\u201323, 2017.","DOI":"10.1039\/C6NR08069C"},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0185","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijcard.2015.03.327","article-title":"Cardiovascular outcomes of intravenous iron in perspective of clinical trials and the use of different iron preparations","volume":"187","author":"Toblli","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.nano.2020.102178_bb0190","series-title":"Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation","author":"Pai","year":"2017"},{"issue":"5","key":"10.1016\/j.nano.2020.102178_bb0195","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1208\/s12248-017-0126-0","article-title":"Physicochemical characterization of iron carbohydrate colloid drug products","volume":"19","author":"Zou","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.nano.2020.102178_bb0200","unstructured":"Seshagiri R. Tata-Venkata, I. L. (US); X. Z. Chicago, I. L. (US); F. G. Gurnee, I. L. (US); M. Wilmette, and L. V. Siddiqui IL (US), \u201cPackaged iron sucrose products,\u201d 2011."},{"key":"10.1016\/j.nano.2020.102178_bb0205","unstructured":"S. A. Pillai, D. Chobisa, D. Urimi, and N. Ravindra, \u201cPharmaceutical glass interactions: a review of possibilities,\u201d J. Pharm. Sci. Res., vol. 8, no. 2, p. 103, 2016."},{"issue":"04","key":"10.1016\/j.nano.2020.102178_bb0210","first-page":"176","article-title":"Differences between original intravenous iron sucrose and iron sucrose similar preparations","volume":"59","author":"Toblli","year":"2009","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0215","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/nyas.13382","article-title":"How to select a nanosimilar","volume":"1407","author":"Astier","year":"2017","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"10","key":"10.1016\/j.nano.2020.102178_bb0220","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1093\/ndt\/gfr024","article-title":"Do two intravenous iron sucrose preparations have the same efficacy?","volume":"26","author":"Rottembourg","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1\u20132","key":"10.1016\/j.nano.2020.102178_bb0225","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.powtec.2010.03.040","article-title":"Influence of handling and storage conditions on morphological and mechanical properties of polymer-coated particles: characterization and modeling","volume":"206","author":"Perfetti","year":"2011","journal-title":"Powder Technol."},{"issue":"3\u20104","key":"10.1016\/j.nano.2020.102178_bb0230","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/sia.2726","article-title":"Characterization challenges for nanomaterials","volume":"40","author":"Baer","year":"2008","journal-title":"Surf. Interface Anal."},{"issue":"102","key":"10.1016\/j.nano.2020.102178_bb0235","doi-asserted-by":"crossref","first-page":"84172","DOI":"10.1039\/C5RA10187E","article-title":"Impact of storage conditions and storage time on silver nanoparticles\u2019 physicochemical properties and implications for their biological effects","volume":"5","author":"Izak-Nau","year":"2015","journal-title":"Rsc Adv."},{"issue":"3","key":"10.1016\/j.nano.2020.102178_bb0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40094-016-0212-1","article-title":"Effect of aging on the properties of TiO2 nanoparticle","volume":"10","author":"Jasbi","year":"2016","journal-title":"J. Theor. Appl. Phys."},{"issue":"1\u20132","key":"10.1016\/j.nano.2020.102178_bb0245","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10948-010-0932-4","article-title":"Properties of iron oxide nanoparticles synthesized at different temperatures","volume":"24","author":"Karaagac","year":"2011","journal-title":"J. Supercond. Nov. Magn."},{"issue":"9","key":"10.1016\/j.nano.2020.102178_bb0250","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.drudis.2015.05.009","article-title":"Metal nanoparticles: a theranostic nanotool against cancer","volume":"20","author":"Sharma","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.nano.2020.102178_bb0255","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/ndt\/15.11.1827","article-title":"Catalytically active iron and bacterial growth in serum of haemodialysis patients after iv iron-saccharate administration","volume":"15","author":"Parkkinen","year":"2000","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"10.1016\/j.nano.2020.102178_bb0260","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1185\/03007995.2011.628304","article-title":"Short-term stability of a new generic sodium ferric gluconate in complex with sucrose","volume":"27","author":"Baribeault","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0265","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/jps.21806","article-title":"Thermodynamic stability assessment of a colloidal iron drug product: sodium ferric gluconate","volume":"99","author":"Yang","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.nano.2020.102178_bb0270","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/106002809002400210","article-title":"Parenteral iron dextran therapy","volume":"24","author":"Kumpf","year":"1990","journal-title":"DICP"},{"issue":"2","key":"10.1016\/j.nano.2020.102178_bb0275","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/j.2055-2335.2013.tb00232.x","article-title":"Stability of diluted iron polymaltose in PVC infusion bags","volume":"43","author":"Patel","year":"2013","journal-title":"J. Pharm. Pract. Res."},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0280","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/ejhpharm-2015-000697","article-title":"Diluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w\/v) in polypropylene bottles and bags: effects on chemical stability","volume":"23","author":"Philipp","year":"2016","journal-title":"Eur J Hosp Pharm"},{"issue":"5","key":"10.1016\/j.nano.2020.102178_bb0285","doi-asserted-by":"crossref","first-page":"9368","DOI":"10.3390\/ijms16059368","article-title":"Different storage conditions influence biocompatibility and physicochemical properties of iron oxide nanoparticles","volume":"16","author":"Zaloga","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.nano.2020.102178_bb0290","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/02656736.2014.913321","article-title":"Magnetic resonance imaging contrast of iron oxide nanoparticles developed for hyperthermia is dominated by iron content","volume":"30","author":"Wabler","year":"2014","journal-title":"Int. J. Hyperth."},{"issue":"7","key":"10.1016\/j.nano.2020.102178_bb0295","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ndt\/gfg074","article-title":"Oxidative stress in end\u2010stage renal disease: an emerging threat to patient outcome","volume":"18","author":"Locatelli","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.nano.2020.102178_bb0300","doi-asserted-by":"crossref","unstructured":"E. Suvikas-Peltonen, S. Hakoinen, E. Celikkayalar, R. Laaksonen, and M. Airaksinen, \u201cIncorrect aseptic techniques in medicine preparation and recommendations for safer practices: a systematic review,\u201d Eur J Hosp Pharm, p. ejhpharm-2016-001015, 2016.","DOI":"10.1136\/ejhpharm-2016-001015"},{"issue":"Suppl. 1","key":"10.1016\/j.nano.2020.102178_bb0305","doi-asserted-by":"crossref","first-page":"c101","DOI":"10.1159\/000328063","article-title":"Renal association clinical practice guideline on anaemia of chronic kidney disease","volume":"118","author":"Mikhail","year":"2011","journal-title":"Nephron Clin. Pract."},{"key":"10.1016\/j.nano.2020.102178_bb0310","unstructured":"\u201cEU clinical trials register.\u201d European Medicines Agency Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands."},{"key":"10.1016\/j.nano.2020.102178_bb0315","article-title":"Intravenous iron therapy in patients with iron deficiency anemia: dosing considerations","volume":"2015","author":"Koch","year":"2015","journal-title":"Anemia, vol."},{"key":"10.1016\/j.nano.2020.102178_bb0320","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/IJNRD.S89704","article-title":"Efficacy and safety of iron isomaltoside (Monofer\u00ae) in the management of patients with iron deficiency anemia","volume":"9","author":"Kalra","year":"2016","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"10.1016\/j.nano.2020.102178_bb0325","doi-asserted-by":"crossref","unstructured":"S. Bhandari, D. Pereira, H. Chappell, and H. Drakesmith, \u201cIntravenous irons: from basic science to clinical practice,\u201d Pharmaceuticals, vol. 11, no. 3, p. 82, 2018.","DOI":"10.3390\/ph11030082"},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0330","first-page":"49","article-title":"Severe hypophosphataemia after intravenous iron administration","volume":"72","author":"Blazevic","year":"2014","journal-title":"Neth J Med"},{"key":"10.1016\/j.nano.2020.102178_bb0335","unstructured":"emc, \u201cVenofer (iron sucrose).\u201d [Online]. Available: https:\/\/www.medicines.org.uk\/emc\/product\/5911\/smpc."},{"key":"10.1016\/j.nano.2020.102178_bb0340","unstructured":"emc, \u201cFerinject (ferric carboxymaltose).\u201d [Online]. Available: https:\/\/www.medicines.org.uk\/emc\/product\/5910\/smpc."},{"key":"10.1016\/j.nano.2020.102178_bb0345","unstructured":"emc, \u201cIron dextran.\u201d [Online]. Available: https:\/\/www.medicines.org.uk\/emc\/product\/48\/smpc."},{"issue":"5","key":"10.1016\/j.nano.2020.102178_bb0350","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/bcp.13189","article-title":"Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions","volume":"83","author":"Bager","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.nano.2020.102178_bb0355","doi-asserted-by":"crossref","unstructured":"J. G. A. Rottembourg, M. Diaconita, and A. Kadri, \u201cThe complete study of the switch from iron-sucrose originator to iron-sucrose similar and vice versa in hemodialysis patients,\u201d J Kidney, vol. 2, no. 1, p. 110, 2016.","DOI":"10.4172\/2472-1220.1000110"},{"key":"10.1016\/j.nano.2020.102178_bb0360","doi-asserted-by":"crossref","unstructured":"M. L. Ag\u00fcera et al., \u201cEfficiency of original versus generic intravenous iron formulations in patients on haemodialysis,\u201d PLoS One, vol. 10, no. 8, p. e0135967, 2015.","DOI":"10.1371\/journal.pone.0135967"},{"key":"10.1016\/j.nano.2020.102178_bb0365","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1111\/hdi.12560","article-title":"The available intravenous iron formulations: history, efficacy, and toxicology","volume":"21","author":"Auerbach","year":"2017","journal-title":"Hemodial. Int."},{"key":"10.1016\/j.nano.2020.102178_bb0370","doi-asserted-by":"crossref","unstructured":"B. S. Barot, P. B. Parejiya, P. K. Shelat, G. B. Shah, D. M. Mehta, and T. V Pathak, \u201cPhysicochemical and toxicological characterization of sucrose-bound polynuclear iron oxyhydroxide formulations,\u201d J. Pharm. Investig., vol. 45, no. 1, pp. 35\u201349, 2015.","DOI":"10.1007\/s40005-014-0143-2"},{"key":"10.1016\/j.nano.2020.102178_bb0375","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jpba.2013.08.005","article-title":"Structural characterization of iron oxide\/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD)","volume":"86","author":"F\u00fctterer","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"3","key":"10.1016\/j.nano.2020.102178_bb0380","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.carbpol.2005.04.019","article-title":"Interactions between iron (III) and sucrose, dextran, or starch in complexes","volume":"61","author":"Somsook","year":"2005","journal-title":"Carbohydr. Polym."},{"issue":"1\u20132","key":"10.1016\/j.nano.2020.102178_bb0385","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1015552311359","article-title":"Physical and chemical characterization of therapeutic iron containing materials: a study of several superparamagnetic drug formulations with the \u03b2-FeOOH or ferrihydrite structure","volume":"136","author":"Funk","year":"2001","journal-title":"Hyperfine Interact."},{"issue":"6","key":"10.1016\/j.nano.2020.102178_bb0390","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2362.2009.02130.x","article-title":"Physicochemical properties of ferumoxytol, a new intravenous iron preparation","volume":"39","author":"Balakrishnan","year":"2009","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.nano.2020.102178_bb0395","series-title":"Colloidal dispersions: suspensions, emulsions, and foams","author":"Morrison","year":"2002"},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0400","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/nyas.13517","article-title":"Iron sucrose: assessing the similarity between the originator drug and its intended copies","volume":"1407","author":"Di Francesco","year":"2017","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9","key":"10.1016\/j.nano.2020.102178_bb0405","doi-asserted-by":"crossref","first-page":"17501","DOI":"10.3390\/ijms140917501","article-title":"Materials characterization of feraheme\/ferumoxytol and preliminary evaluation of its potential for magnetic fluid hyperthermia","volume":"14","author":"Bullivant","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nano.2020.102178_bb0410","doi-asserted-by":"crossref","unstructured":"H. J. Manley and D. W. Grabe, \u201cDetermination of iron sucrose (Venofer) or iron dextran (DexFerrum) removal by hemodialysis: an in-vitro study,\u201d BMC Nephrol., vol. 5, no. 1, p. 1, 2004.","DOI":"10.1186\/1471-2369-5-1"},{"issue":"6","key":"10.1016\/j.nano.2020.102178_bb0415","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1093\/ndt\/gfr711","article-title":"Effects of intravenous iron on mononuclear cells during the haemodialysis session","volume":"27","author":"Martin-Malo","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"10.1016\/j.nano.2020.102178_bb0420","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1365-2362.2003.01264.x","article-title":"Effect of iron sucrose on human peritoneal mesothelial cells","volume":"33","author":"Br\u0229borowicz","year":"2003","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.nano.2020.102178_bb0425","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.taap.2018.04.028","article-title":"Feraheme\u00ae suppresses immune function of human T lymphocytes through mitochondrial damage and mitoROS production","volume":"350","author":"Shah","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0430","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000451060","article-title":"Distinct in vitro complement activation by various intravenous iron preparations","volume":"45","author":"Hempel","year":"2017","journal-title":"Am. J. Nephrol."},{"issue":"02","key":"10.1016\/j.nano.2020.102178_bb0435","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1055\/s-0031-1296176","article-title":"Physicochemical and toxicological characterization of a new generic iron sucrose preparation","volume":"61","author":"Meier","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.nano.2020.102178_bb0440","article-title":"Oxidative stress in hemodialysis patients: a review of the literature","volume":"vol. 2017","author":"Liakopoulos","year":"2017","journal-title":"Oxid. Med. Cell. Longev"},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0445","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10534-014-9801-0","article-title":"Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity","volume":"28","author":"Praschberger","year":"2015","journal-title":"Biometals"},{"issue":"3","key":"10.1016\/j.nano.2020.102178_bb0450","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1023\/A:1022547819506","article-title":"Comparison of injectable iron complexes in their ability to iron load tissues and to induce oxidative stress","volume":"16","author":"Legssyer","year":"2003","journal-title":"Biometals"},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0455","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-008-0120-5","article-title":"Body iron metabolism and pathophysiology of iron overload","volume":"88","author":"Kohgo","year":"2008","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0460","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.12403","article-title":"Nanomedicines: addressing the scientific and regulatory gap","volume":"1313","author":"Tinkle","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0465","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-0609.2012.01783.x","article-title":"Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron","volume":"89","author":"Ghoti","year":"2012","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.nano.2020.102178_bb0470","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bjhh.2016.05.009","article-title":"Iron deficiency in cancer patients","volume":"38","author":"Naoum","year":"2016","journal-title":"Rev. Bras. Hematol. Hemoter."},{"issue":"2","key":"10.1016\/j.nano.2020.102178_bb0475","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/ckj\/sfv142","article-title":"Safety concerns about intravenous iron therapy in patients with chronic kidney disease","volume":"9","author":"Del Vecchio","year":"2016","journal-title":"Clin. Kidney J."},{"issue":"7","key":"10.1016\/j.nano.2020.102178_bb0480","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/ndt\/gfh811","article-title":"Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients","volume":"20","author":"Walters","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.nano.2020.102178_bb0485","doi-asserted-by":"crossref","unstructured":"B. V Stef\u00e1nsson, B. Haraldsson, and U. Nilsson, \u201cAcute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran,\u201d Nephron Clin. Pract., vol. 118, no. 3, pp. c249\u2013c256, 2011.","DOI":"10.1159\/000321645"},{"issue":"suppl_1","key":"10.1016\/j.nano.2020.102178_bb0490","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ckj\/sfx043","article-title":"Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions","volume":"vol. 10","author":"Macdougall","year":"2017","journal-title":"Clin. Kidney J."},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0495","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","article-title":"Iron management in chronic kidney disease: conclusions from a \u2018Kidney Disease: Improving Global Outcomes\u2019(KDIGO) Controversies Conference","volume":"89","author":"Macdougall","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.nano.2020.102178_bb0500","doi-asserted-by":"crossref","unstructured":"T. Avni, A. Bieber, A. Grossman, H. Green, L. Leibovici, and A. Gafter-Gvili, \u201cThe safety of intravenous iron preparations: systematic review and meta-analysis,\u201d in Mayo Clinic Proceedings, 2015, vol. 90, no. 1, pp. 12\u201323.","DOI":"10.1016\/j.mayocp.2014.10.007"},{"issue":"1","key":"10.1016\/j.nano.2020.102178_bb0505","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/ajkd.2002.33917","article-title":"Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury","volume":"40","author":"Zager","year":"2002","journal-title":"Am. J. kidney Dis."},{"key":"10.1016\/j.nano.2020.102178_bb0510","unstructured":"P. Geisser and A. M\u00fcller, \u201cPharmacokinetics of iron salts and ferric hydroxide-carbohydrate complexes,\u201d Arzneimittelforschung, vol. 37, no. 1A, pp. 100\u2013104, 1987."}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963420300307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963420300307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:10:42Z","timestamp":1761549042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963420300307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":102,"alternative-id":["S1549963420300307"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2020.102178","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2020.102178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102178"}}